Haleon plc

Haleon plc, a UK-based pharmaceutical preparation manufacturer, is committed to climate action. For 2025, Haleon plc projects total emissions of approximately 10.15 billion kg CO2e, comprising about 52.9 million kg CO2e from Scope 1 emissions, 132.25 million kg CO2e from Scope 2 (location-based), and approximately 7.49 billion kg CO2e from Scope 3 emissions.

In 2024, the company's Scope 1 emissions were approximately 68 million kg CO2e, while Scope 2 (location-based) emissions were around 124 million kg CO2e. Scope 3 emissions for the same year totalled about 3.9 billion kg CO2e.

In 2023, Haleon plc reported total emissions of approximately 2.9 billion kg CO2e, with Scope 1 emissions at roughly 60 million kg CO2e and Scope 2 (location-based) at about 142 million kg CO2e. Scope 3 emissions for 2023 were approximately 2.7 billion kg CO2e.

Looking back to 2022, total emissions were approximately 2.89 billion kg CO2e. This included around 56 million kg CO2e from Scope 1 emissions and 140 million kg CO2e from Scope 2 (location-based) emissions. Scope 3 emissions in 2022 were approximately 2.7 billion kg CO2e.

Haleon plc has set ambitious near-term targets validated by the Science Based Targets initiative (SBTi). The company commits to reducing absolute Scope 1 and 2 GHG emissions by 95% by FY2030 from a FY2020 base year. Additionally, Haleon plc aims to reduce absolute Scope 3 GHG emissions by 42% by FY2030 from a FY2022 base year, covering categories such as purchased goods and services, capital goods, fuel- and energy-related activities, upstream transportation and distribution, waste generated in operations, upstream leased assets, and downstream transportation and distribution. The company is also committed to achieving net-zero carbon emissions from source to sale by 2040, aligning with the Climate Pledge and Race to Zero initiatives.